Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal.
BACKGROUND
Chemoprophylaxis of contacts of infectious tuberculosis (TB) cases is recommended for TB control, particularly in endemic countries, but is hampered by the difficulty to diagnose latent TB infection (LTBI), classically assessed through response to the Tuberculin Skin Test (TST). Interferon-gamma release assays (IGRA) are proposed new tools to diagnose LTBI, but there are limited data on their ability to predict the development of active TB disease. To address this, we investigated the response to TST and IGRA in household contacts of infectious TB cases in a TB high-burden country and the potential correlation with development of TB.


RESULTS
Prospective household contacts study conducted in two health centres in Dakar, Senegal. A total of 2679 household contacts of 206 newly detected smear and/or culture positive index TB cases aged 18 years or greater were identified A TST was performed in each contact and an ESAT6/CFP10 ELISPOT assay performed in a random sample of those. Contacts were followed-up for 24 months. TB was diagnosed in 52 contacts, an incidence rate of 9.27/1000 person-years. In univariable analysis, the presence of positive TST (> or = 10 mm) and ELISPOT (>32 SFC/million PBMC) responses at baseline were associated with active TB during follow-up: Rate Ratio [RR] = 2.32 (95%CI:1.12-4.84) and RR = 2.09 (95%CI:0.83-5.31), respectively. After adjustment for age, sex and proximity to index case, adjusted RRs were 1.51 (95%CI:0.71-3.19) and 1.98 (95%CI:0.77-5.09), respectively. Restricting analysis to the 40 microbiologically confirmed cases, the adjusted RR for positive ELISPOT was 3.61 (95%CI:1.03-12.65). The median ELISPOT response in contacts who developed TB was 5-fold greater than in those who did not develop TB (p = 0.02).


CONCLUSIONS
TST and IGRAs are markers of a contact of the immune system with tubercle bacilli. In a TB endemic area, a high ELISPOT response may reflect increased bacterial replication that may subsequently be associated with development of TB disease and may have a prognostic value. Further longitudinal data are needed to assess whether IGRAs are reliable markers to be used for targeting chemoprophylaxis.
Lienhardt
Christian
C
Institut de Recherche pour le Développement, Programme Tuberculose, Dakar, Senegal. lienhardtc@who.int
Fielding
Katherine
K
Hane
Abdoul A
AA
Niang
Aliou
A
Ndao
Cheikh T
CT
Karam
Farba
F
Fletcher
Helen
H
Mbow
Fatou
F
Gomis
Jules-François
JF
Diadhiou
Raymond
R
Diadhiou
Roger
R
Toupane
Maxime
M
Dieye
Tandakha
T
Mboup
Souleymane
S
D000293:Adolescent; D000328:Adult; D002648:Child; D005191:Family Characteristics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D015994:Incidence; D007371:Interferon-gamma / Q000032:analysis* / Q000378:metabolism*; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D012675:Senegal / Q000453:epidemiology; D013997:Time Factors; D014374:Tuberculin Test / Q000379:methods*; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000453:epidemiology; D055815:Young Adult
D007371:Interferon-gamma
Epidemiol Rev. 2001;23(2):288-301
12192738
Int J Tuberc Lung Dis. 2008 Jan;12(1):50-6
18173877
PLoS One. 2009 Dec 14;4(12):e8257
20011589
Clin Infect Dis. 1993 Dec;17(6):968-75
8110954
Lancet Infect Dis. 2004 Dec;4(12):761-76
15567126
Expert Rev Mol Diagn. 2006 May;6(3):413-22
16706743
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55
16357824
Ann Intern Med. 2008 Aug 5;149(3):177-84
18593687
PLoS Med. 2007 Jun;4(6):e192
17564487
PLoS One. 2008 Jan 16;3(1):e1441
18197251
Am J Respir Crit Care Med. 2008 May 15;177(10):1164-70
18276940
Int J Tuberc Lung Dis. 2009 Jan;13(1):84-92
19105884
Clin Infect Dis. 2007 Oct 1;45(7):837-45
17806047
Am J Respir Crit Care Med. 2002 Oct 15;166(8):1016-7
12379540
Med Trop (Mars). 2005;65(1):43-8
15903076
Am J Epidemiol. 2002 Jun 1;155(11):1066-73
12034586
PLoS One. 2008 Jan 02;3(1):e1379
18167540
Int J Tuberc Lung Dis. 2008 Nov;12(11):1286-94
18926039
Trends Mol Med. 2007 May;13(5):175-82
17418641
Eur Respir J. 2009 May;33(5):956-73
19407047
Ann Intern Med. 2008 Dec 2;149(11):777-87
18936496
Lancet. 2001 Jun 23;357(9273):2017-21
11438135
Infect Immun. 2001 Oct;69(10):6554-7
11553606
Nat Rev Microbiol. 2009 Dec;7(12):845-55
19855401
Ann Intern Med. 2007 Mar 6;146(5):340-54
17339619
Clin Infect Dis. 1996 Apr;22(4):683-704
8729208
Lancet. 2000 Sep 23;356(9235):1099-104
11009160
J Clin Microbiol. 2002 Feb;40(2):704-6
11826002